Reward and risk in Hong Kong's new listing rules for biotech firms


Allowing biotech firms to list in the city before they generate revenue is a bonus for the firms, but investors need to be aware of the pitfalls Hong Kong's impending move to allow biotechnology firms to list on the city's stock market before they generate any revenue is a bonus for companies, but for investors new to the sector a healthy dose of risk awareness is needed, according to industry executives. Bao Jun, the chief business officer and acting chief financial officer of Beijing Shenogen Pharma Group, which had considered listing on the Nasdaq market in the US, now plans to list in Hong Kong as soon as this year, followed by a listing on a mainland China bourse when it meets requirements there.



from Biotech News